Sign in Subscribe
Cancer research

Phase 1 Clinical Trial to Study Integrating CAR T-Cell Therapy with Bone Marrow Transplant for High-Risk Blood Cancers

Strategic Insights

— 1 min read

The National Cancer Institute (NCI) has listed a Phase 1 clinical trial to study the integration of CAR T-cell therapy with bone marrow transplant, also known as allogeneic hematopoietic cell transplantation, for patients with high-risk blood cancers. The trial, led by principal investigator Christopher G. Kanakry, M.D., aims to enroll 155 participants in the United States to test the safety and efficacy of this combined treatment approach.

Key Takeaways:

  • The trial aims to enroll 155 participants aged 18 to 75 years with aggressive blood cancers expressing the CD19 protein.
  • Participants will undergo imaging scans, blood tests, and tests of their heart and lung function before receiving the treatment.
  • The treatment involves the use of CAR T-cell therapy and bone marrow transplant from a healthy related donor aged 12 years or older.
  • The trial will assess the safety and efficacy of this combined treatment approach over a 5-year period, with frequent follow-up visits and periodic examinations.
  • The trial is currently not open for recruiting, and interested participants must check the ClinicalTrials.gov website for updates.

Statistics:

  • The trial will enroll 155 participants in the United States.
  • The treatment involves the use of CAR T-cell therapy and bone marrow transplant from a healthy related donor.
  • The trial will assess the safety and efficacy of this combined treatment approach over a 5-year period.
  • Participants will undergo 4 to 6 weeks of hospitalization followed by 2 to 3 months of frequent visits and periodic examinations.
  • The trial is led by principal investigator Christopher G. Kanakry, M.D.

Sources:

  • ClinicalTrials.gov (NCT07162038)
  • National Cancer Institute (NCI)
  • Contify.com ( quotes and references only)

Read more